Outlook Therapeutics (OTLK) Other Non-Current Assets (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Other Non-Current Assets of $320290.0 for Q1 2026, down 18.67% year-over-year from $393831.0 in Q1 2025, and down 7.46% quarter-over-quarter from $346111.0 in Q4 2025.
Outlook Therapeutics (OTLK) Other Non-Current Assets (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Other Non-Current Assets for 12 consecutive years, with $320290.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 18.67% year-over-year to $320290.0; the TTM figure through Mar 2026 stood at $320290.0 (down 18.67% YoY), while the FY2025 annual figure was $417523.0, down 4.95% from the prior year.
- Other Non-Current Assets retreated to $320290.0 in Q1 2026 per OTLK's latest filing, from $346111.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $589365.0 in Q2 2023 and bottomed at $113850.0 in Q1 2023.
- Historically, Other Non-Current Assets has averaged $351728.0 across 5 years, with a median of $415974.0 in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets sank 86.79% — and 2023, when it surged 319.91%.
- Outlook Therapeutics' Other Non-Current Assets stood at $126442.0 in 2022, then surged by 283.04% to $484320.0 in 2023, then fell by 14.11% to $415974.0 in 2024, then declined by 16.8% to $346111.0 in 2025, then fell by 7.46% to $320290.0 in 2026.
- Business Quant data shows OTLK's Other Non-Current Assets at $320290.0 in Q1 2026, $346111.0 in Q4 2025, and $417523.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | 304,048.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 320,290.00 |
| Dec 31, 2025 | 346,111.00 |
| Sep 30, 2025 | 417,523.00 |
| Jun 30, 2025 | 464,388.00 |
| Mar 31, 2025 | 393,831.00 |
| Dec 31, 2024 | 415,974.00 |
| Sep 30, 2024 | 439,283.00 |
| Jun 30, 2024 | 479,229.00 |
| Mar 31, 2024 | 473,241.00 |
| Dec 31, 2023 | 484,320.00 |
| Sep 30, 2023 | 501,299.00 |
| Jun 30, 2023 | 589,365.00 |
| Mar 31, 2023 | 113,850.00 |
| Dec 31, 2022 | 126,442.00 |
| Sep 30, 2022 | 132,015.00 |
| Jun 30, 2022 | 140,356.00 |
| Mar 31, 2022 | 141,859.00 |
| Dec 31, 2021 | 156,702.00 |
| Sep 30, 2021 | 174,590.00 |
| Jun 30, 2021 | 194,355.00 |